Analyst firms · Wedbush · REPL

Wedbush REPL price target and rating history

Replimune Group Inc. (REPL) · Health Care

Wedbush rates Replimune Group Inc. (REPL) Outperform with a $12 price target, as of its latest action on Aug 7, 2026. It has published 5 rating actions on REPL since July 2025, including 3 upgrades and 2 downgrades. Across 5 firms with a REPL price target in the last 12 months, the median target is $12. Wedbush's target matches it.

Current rating
Outperform
Price target
$12
Median target, all firms
$12
Actions on REPL
5

Wedbush price target on REPL

$18$10$22026
Wedbush price target on REPL, each point a stated target, July 2025 to August 2026.

Every Wedbush rating on REPL

How other firms rate REPL

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
WedbushOutperform$12Aug 7, 2026
Leerink PartnersOutperform$17Aug 4, 2026
Cantor FitzgeraldOverweightJul 31, 2026
BMO Capital MarketsOutperform$16Jun 30, 2026
JefferiesHold$2Apr 13, 2026
H.C. WainwrightSellApr 13, 2026
Piper SandlerNeutral$4Apr 10, 2026

Questions about Wedbush and REPL

What is Wedbush's price target for REPL?
Wedbush's latest stated price target for Replimune Group Inc. (REPL) is $12, from its action on Aug 7, 2026.
What is Wedbush's rating on REPL?
Wedbush rates REPL Outperform, a bullish rating, as of Aug 7, 2026.
When did Wedbush last change its view on REPL?
On Aug 7, 2026, Wedbush upgrades to Outperform from Neutral, price target $12.
How does Wedbush's REPL target compare with other analysts?
Across 5 firms with a REPL price target in the last 12 months, the median target is $12. Wedbush's target matches it.

More REPL rating histories

All Wedbush ratingsREPL news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.